Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Mar 24, 2021 11:23am

192 Views

Post# 32866336

RE:RE:RE:RE:RE:RE:RE:RE:RE:NASDAQ

To be honest, when ATE announced that they would upgarde to OTCQX in Feb, I knew Nasdaq is not something in near term, which is deeply disspointed us. However, since ATE has enough cash c$73M in bank, uplisting to Nasdaq becomes less important to keep the company afloat. The main focus of this company is developing drugs - financing is only something required but not sufficent condition for its success. We seldom see any companies being great in share price but bad in business (except GameStop). We will be well rewarded when the fruits are fully ripened. Just be patient. BTW, I just picked up another few thousands of ATE today. Now I have 158K shares in hands. GLTA longs!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario